Aarskog-Scott syndrome

Synonyms and Keywords: Aarskog disease, Aarskog-Scott syndrome, AAS, Faciodigitogenital syndrome, Faciogenital dysplasia, FGDY, Scott Aarskog syndrome

Aarskog-Scott syndrome
ICD-10	Q87.1
ICD-9	759.89
OMIM	100050
DiseasesDB	29329

Overview

Aarskog-Scott syndrome is a rare inherited disease distinguish by short stature, facial abnormalities, skeletal and genital anomalies. The Aarskog-Scott syndrome (AAS) is also known as the Aarskog syndrome, faciodigitogenital syndrome, shawl scrotum syndrome and facial genital dysplasia. In The United States of America in order to categorise a condition as a rare disease it should affect fewer than 200,000 people. Rare diseases also called as orphan diseases. Orphan Drug Act was passed on 1983 by congress for the rare diseases. Today an average of 25-30 million americans have been reported with rare diseases. The number of people with individual rare disease may be less but overall the number of people with rare diseases are large in number.

Historical Perspective

• Aarskog-Scott syndrome (AAS) was first described by Aarskog, a Norwegian pediatrician and human geneticist, in 1970.

• The association between ligamentous laxity which results in hyperextensibility of the fingers, genu recurvatum,flat feet and Aarskog-Scott syndrome (AAS) was made by Scott in year 1971.
• In 1973, Sugarman et al described an Mexican-American family in which 2 half brothers and their 2 maternal uncles had Aarskog syndrome.
• In 1993, Teebi et al suggested that the disease Aarskog-Scott syndrome (AAS) follows autosomal dominant inheritance.
• In 1978, Escobar and Weaver described a patient who is had symptoms of Noonan syndrome than Aarskog-Scott syndrome (AAS).

Genetic

X-linked recessive inheritance.

Aarskog-Scott syndrome is transmitted in an X-linked recessive manner. The sons of female carriers are at 50% risk of being affected with the syndrome. The daughters of female carriers are at 50% risk of being carriers themselves. Females may have mild manifestations of the syndrome. The syndrome is caused by mutation in a gene called FGDY1 in band p11.21 on the X chromosome.

Eponym

The syndrome is named for Dagfinn Aarskog, a Norwegian pediatrician and human geneticist who first described it in 1970, and for Charles I. Scott, Jr., an American medical geneticist who independently described the syndrome in 1971.

Description

The Aarskog-Scott syndrome is a disorder with short stature, hypertelorism, downslanting palpebral fissures, anteverted nostrils, joint laxity, shawl scrotum, and mental retardation. The physical phenotype varies with age and postpuberal males may have only minor remnant manifestations of the prepuberal phenotype.

Frequent features

• Growth
  • mild to moderate short stature evident by 1-3 years of age
  • delayed adolescent growth spurt
• Performance
  • slight (dull normal) to moderate mental deficiency
  • hyperactivity and attention deficit
  • social performance usually good
• Face
  • rounded face
  • widow's peak hairline
  • wide-set eyes (hypertelorism)
  • droopy eyelids (blepharoptosis)
  • downslanting eye slits (palpebral fissures)
  • small nose with nostrils tipped forward (anteverted)
  • underdeveloped mid-portion of the face (maxilla
  • wide groove above the upper lip (broad philtrum)
  • crease below the lower lip
  • delayed eruption of teeth
  • top portion (upper helix) of the ear folded over slightly
• Hands and feet
  • small, broad hands and feet
  • short fingers and toes (brachydactyly)
  • in-curving of the 5th finger (clinodactyly)
  • mild webbing between the fingers and toes
  • single transverse "simian crease" in palm
  • broad thumbs and big toes
• Neck
  • short neck
  • webbing of sides of the neck
• Chest
  • mild pectus excavatum (sunken chest)
• Abdomen
  • protruding navel
  • inguinal hernias
• Genitalia
  • Shawl Scrotum
  • undescended testicles

Diagnosis

Genetic testing may be available for mutations in the FGDY1 gene. Genetic counseling is indicated for individuals or families who may carry this condition, as there are overlapping features with Fetal alcohol syndrome.

Treatment

Surgery may be required to correct some of the anomalies, and orthodontic treatment may be used to correct some of the facial abnormalities. Trials of growth hormone have not been effective to treat short stature in this disorder.

Support Group

The MAGIC Foundation for Children's Growth is a support group for Aarskog-Scott syndrome and can be found at www.magicfoundation.org.

Prognosis

Mild degrees of mental slowness may be present, but affected children usually have good social skills. Some males may exhibit reduced fertility.

Complications

Some recent findings have included cystic changes in the brain and generalized seizures. There may be difficulty growing in the first year of life in up to one-third of cases. Misaligned teeth may require orthodontic correction. An undescended testicle will require surgery.

Molecular biology

The Aarskog-Scott syndrome is due to mutation in the FGD1 gene. FGD1 encodes a guanine nucleotide exchange factor (GEF) that specifically activates Cdc42, a member of the Rho (Ras homology) family of the p21 GTPases. By activating Cdc42, FGD1 protein stimulates fibroblasts to form filopodia, cytoskeletal elements involved in cellular signaling, adhesion, and migration. Through Cdc42, FGD1 protein also activates the c-Jun N-terminal kinase (JNK) signaling cascade, a pathway that regulates cell growth, apoptosis, and cellular differentiation.

Within the developing mouse skeleton, FGD1 protein is expressed in precartilaginous mesenchymal condensations, the perichondrium and periostium, proliferating chondrocytes, and osteoblasts. These results suggest that FGD1 signaling may play a role in the biology of several different skeletal cell types including mesenchymal prechondrocytes, chondrocytes, and osteoblasts. The characterization of the spatiotemporal pattern of FGD1 expression in mouse embryos has provided important clues to the understanding of the pathogenesis of Aarskog-Scott syndrome. It appears likely that the primary defect in Aarskog-Scott syndrome is an abnormality of FGD1/Cdc42 signaling resulting in anomalous embryonic development and abnormal endochondral and intramembranous bone formation